2-chloro-9-(2,4-difluorobenzyl)-1H-purin-6(9H)-one | 1094567-99-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-chloro-9-(2,4-difluorobenzyl)-1H-purin-6(9H)-one
• 英文别名: 2-chloro-9-[(2,4-difluorophenyl)methyl]-1H-purin-6-one
• CAS: 1094567-99-3
• 化学式: C₁₂H₇ClF₂N₄O
• 分子量: 296.664
• InChiKey: KQQHXHZKKQXLOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  63.57
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2-chloro-9-(2,4-difluorobenzyl)-1H-purin-6(9H)-one 在 potassium carbonate 、 三乙胺 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 9-[(2,4-Difluorophenyl)methyl]-1-ethyl-2-[(1-hydroxy-2-methylpropan-2-yl)amino]purin-6-one
  参考文献：
  名称：

  Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 2

  摘要：

  Novel P2X(7) antagonists were developed using a purine scaffold. These compounds were potent and selective at the P2X(7) receptor in human and rodent as well as efficacious in rodent pain models. Compound 15a was identified to have oral potency in several pain models in rodent similar to naproxen, gabapentin and pregabalin. Structure-activity relationship (SAR) development and results of pain models are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.037
• 作为产物：
  描述：

  2,4-二氟溴苄 在 potassium carbonate 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 39.0h， 生成 2-chloro-9-(2,4-difluorobenzyl)-1H-purin-6(9H)-one
  参考文献：
  名称：

  [EN] DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
  [FR] DÉRIVÉS DE 7,8-DIHYDRO-1H-IMIDAZO[2,1-B]PURIN-4(5H)-ONE ET PROCÉDÉS D'UTILISATION ASSOCIÉS

  摘要：

  本发明涉及7,8-二氢-1H-咪唑[2,1-b]嘌呤-4(5H)-酮的衍生物，以及其组合物和治疗或预防疼痛或炎症性疾病的使用方法。

  公开号：

  WO2011079000A1

文献信息

• Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 1
  作者：Julius J. Matasi、Stephanie Brumfield、Deen Tulshian、Michael Czarnecki、William Greenlee、Charles G. Garlisi、Hongchen Qiu、Kristine Devito、Shu-Cheng Chen、Youngliang Sun、Rosalia Bertorelli、William Geiss、Van-Duc Le、Gregory S. Martin、Samuel A. Vellekoop、James Haber、Melissa L. Allard

  DOI：10.1016/j.bmcl.2011.04.034

  日期：2011.6

  Structure–activity relationship (SAR) efforts around our initial lead compound 1 led to the identification of potent P2X7 receptor antagonists with improved pharmacokinetic profiles. These compounds were potent and selective at the P2X7 receptor in both human and rodent. Compound (entry 31) exhibited oral efficacy in the rat MIA and CCI pain models.

  围绕我们最初的先导化合物1的结构-活性关系（SAR）的努力导致鉴定出具有改善的药代动力学特征的有效P2X 7受体拮抗剂。这些化合物在人和啮齿动物中均对P2X 7受体有效且具有选择性。化合物（第31项）在大鼠MIA和CCI疼痛模型中表现出口服功效。
• POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF
  申请人：Tulshian Deen

  公开号：US20110065738A1

  公开（公告）日：2011-03-17

  The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.

  本发明涉及多环鸟嘌呤衍生物，包括多环鸟嘌呤衍生物的组合物和使用多环鸟嘌呤衍生物治疗疼痛或炎症性疾病的方法。
• DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
  申请人：Tulshian Deen

  公开号：US20120316176A1

  公开（公告）日：2012-12-13

  The present invention relates to derivatives of 7,8-dihydro-1H-imidazo[2,1-b]purin-4(5H)-one, compositions thereof and methods of use thereof for treating or preventing pain or an inflammatory disease.

  本发明涉及7,8-二氢-1H-咪唑[2,1-b]嘌呤-4(5H)-酮的衍生物，以及其组合物和使用方法，用于治疗或预防疼痛或炎症性疾病。
• DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2523561A1

  公开（公告）日：2012-11-21
• FILM-SHAPED PREPARATION COMPRISING OILY SUBSTANCES FOR ORAL ADMINISTRATION
  申请人：Müller Markus

  公开号：US20110064830A1

  公开（公告）日：2011-03-17

  Water-soluble, solid, film-shaped preparations comprising at least one film-forming polymer selected from the group consisting of the fully and partially hydrolyzed polyvinyl alcohols, and at least one water-insoluble, oily liquid which is incorporated into the film-forming polymer and amounts to at least 30 percent by weight, relative to the dry portion of the preparation. Methods for producing the preparations and the use thereof are also provided.